Welcome to our dedicated page for Provectus Biopha SEC filings (Ticker: PVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings from Provectus Biopharmaceuticals (PVCT) can feel more like lab reports than corporate disclosures; pages of PV-10 safety data, grant agreements, and cash-runway tables leave many investors searching for a translator. If you’ve ever typed “Provectus Biopharmaceuticals SEC filings explained simply” or wondered where the “Provectus Biopharmaceuticals annual report 10-K simplified” lives, you’re not alone. Even locating a single “Provectus Biopharmaceuticals quarterly earnings report 10-Q filing” or an “Provectus Biopharmaceuticals 8-K material events explained” update can consume hours.
Stock Titan eliminates that friction. Our AI deciphers complex biotechnology language so you can instantly grasp PV-10 trial progress, dilution risk, and regulatory milestones. From “Provectus Biopharmaceuticals insider trading Form 4 transactions” and “Provectus Biopharmaceuticals Form 4 insider transactions real-time” to section-by-section breakdowns of research spend, every document arrives with plain-English summaries, red-flag alerts, and keyword search. Need a “Provectus Biopharmaceuticals proxy statement executive compensation” overview or deeper “Provectus Biopharmaceuticals earnings report filing analysis”? One dashboard, real-time EDGAR feeds, and AI-driven context deliver it—ideal for anyone understanding Provectus Biopharmaceuticals SEC documents with AI.
Use these insights the way professionals do:
- Track PV-10 clinical milestones and R&D burn straight from 10-K and 10-Q data
- Flag financing rounds, FDA designations, or trial suspensions the moment an 8-K posts
- Identify “Provectus Biopharmaceuticals executive stock transactions Form 4” patterns before market-moving news
No more wading through chemistry appendices—Stock Titan turns every Provectus filing into clear, actionable intelligence moments after it hits EDGAR.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted a 2024 unsecured convertible promissory note into equity on September 19, 2025. The $100,000 8% note, originally issued under the companys 2024 financing and convertible at $2.862 per share into Series D-1 Preferred Stock, converted into 37,760 shares of Series D-1 Preferred Stock on that date. Each Series D-1 share is convertible into ten shares of common stock, so the conversion corresponds to 377,600 shares of common stock. Following the transaction, Mr. Pershing beneficially owned 2,418,447 shares of common stock. The Series D-1 will automatically convert to common on June 20, 2026 unless earlier converted under its terms.
Insider transaction summary: The company's CEO and a director, Edward Pershing, acquired an 8% unsecured convertible promissory note with a principal amount of $35,000 issued under the issuer's 2025 financing, which is convertible at $2.862 per share into Series D-1 Convertible Preferred Stock. The note may be voluntarily converted at any time while outstanding and will automatically convert into Series D-1 Preferred Stock one year after issuance. Each Series D-1 Preferred share converts into 10 shares of common stock, and the reported Series D-1 Preferred position equals 12,230 shares (effectively 122,300 common shares if converted). The Series D-1 Preferred will automatically convert into common on the specified conversion date absent earlier conversion.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals (PVCT), reported a transaction dated 09/11/2025. He acquired an 8% unsecured convertible promissory note with a principal amount of $35,000 that is convertible into Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share. Following the reported transaction he beneficially owns 12,230 shares of Series D-1 Preferred Stock. Each Series D-1 Preferred share is convertible into 10 shares of common stock, and the Series D-1 Preferred will automatically convert into common stock on June 26, 2026 unless converted earlier. The Note will automatically convert into Series D-1 Preferred twelve months after issuance if not voluntarily converted earlier.
FAQ
What is the current stock price of Provectus Biopha (PVCT)?
What is the market cap of Provectus Biopha (PVCT)?
